Detalhe da pesquisa
1.
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia.
Blood
; 141(9): 996-1006, 2023 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36108341
2.
Characterization of B-cell receptor clonality and immunoglobulin gene usage at multiple time points during active SARS-CoV-2 infection.
J Med Virol
; 95(10): e29179, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37877800
3.
Phase 2 study of ibrutinib in classic and variant hairy cell leukemia.
Blood
; 137(25): 3473-3483, 2021 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33754642
4.
Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia.
Oncologist
; 25(1): e170-e177, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31628266
5.
Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up.
Blood
; 131(21): 2331-2334, 2018 05 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-29487070
6.
Population pharmacokinetics, efficacy, and safety of moxetumomab pasudotox in patients with relapsed or refractory hairy cell leukaemia.
Br J Clin Pharmacol
; 86(7): 1367-1376, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32077130
7.
Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.
Blood
; 130(14): 1620-1627, 2017 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28983018
8.
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.
Blood
; 129(5): 553-560, 2017 02 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27903528
9.
Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience.
Haematologica
; 108(6): 1676-1679, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36546416
10.
Update on hairy cell leukemia.
Clin Adv Hematol Oncol
; 16(3): 205-215, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29742076
11.
Removing a hair of doubt about BRAF targeting.
Blood
; 125(8): 1199-200, 2015 Feb 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-25700421
12.
Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes.
Proc Natl Acad Sci U S A
; 111(23): 8571-6, 2014 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24799704
13.
Immunotoxins for leukemia.
Blood
; 123(16): 2470-7, 2014 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-24578503
14.
Designing the furin-cleavable linker in recombinant immunotoxins based on Pseudomonas exotoxin A.
Bioconjug Chem
; 26(6): 1120-8, 2015 Jun 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-25997032
15.
Characterization of CD22 expression in acute lymphoblastic leukemia.
Pediatr Blood Cancer
; 62(6): 964-9, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25728039
16.
Immunotoxin therapy of cancer.
Nat Rev Cancer
; 6(7): 559-65, 2006 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-16794638
17.
Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes.
Proc Natl Acad Sci U S A
; 109(29): 11782-7, 2012 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-22753489
18.
Cladribine Analogues via O6-(Benzotriazolyl) Derivatives of Guanine Nucleosides.
Molecules
; 20(10): 18437-63, 2015 Oct 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-26473811
19.
Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
Cancer
; 120(21): 3311-9, 2014 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24989332
20.
The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.
Br J Haematol
; 166(2): 177-88, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24697238